Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Intravenous Immunoglobulin Market size was over USD 16.5 billion in 2024 and is estimated to reach USD 43.9 billion by the end of 2037, expanding at a CAGR of 8.5% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of intravenous immunoglobulin is assessed at USD 17.9 billion.
Intravenous immunoglobulin (IVIG) is a therapy that combines immunoglobulins contributed by diverse people to provide remedies for countless disorders. According to the NLM article published in July 2023, immunoglobulin exists either as 5% (50 mg/dL) or 10% (100 mg/dL) liquid or as lyophilized preparations. Based on this, IVIG is managed intravenously, and the half-life of a typical intravenous immunoglobulin infusion is about 3 to 4 weeks. It is usually delivered through a drop into a vein, known as intravenous infusion. It is also given as an injection into a muscle to upsurge immunoglobulin levels by succeeding other treatments. Therefore, all these factors are readily driving the upliftment of the IVIG market internationally.
The intravenous immunoglobulin market is also driven based on immune thrombocytopenia (ITP) which is an autoimmune hematological disorder considered by augmented platelet demolition and reduced platelet production. In such a scenario, patients are usually prescribed IVIG infusion as it is resource-intensive. However, it is highly used to aid rare disorders, and in this regard, a clinical study was conducted which was published by NLM in March 2021 to derive its payer’s pricing in different countries. The costs of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treatment with IVIG application was £49,430 (USD 63,932.7) in the UK and €45,332 (USD 49,098.4) in Germany, thus driving market evolution.
Care Cost of IVIG Treatments Across Countries
|
IVIG Treatments Study |
Countries |
Price Per Patient |
|
Le Masson |
France |
€48,189 (USD 52,199.0) per year at home €91,798 (USD 99,436.9) per year in hospital enditemize |
|
Guptill |
USA |
USD 108,016 per year |
|
Divino |
USA |
USD 136,892 per year |
Source: NLM March 2021
Intravenous Immunoglobulin Sector: Growth Drivers and Challenges
Growth Drivers
- High incidence of immunodeficiency illness: This condition has a tendency to impair the immune system's capability to compete against infections, which can be either inherited or acquired. According to the February 2021 NLM article, an estimated 1 in 10,000 of the global population is affected by primary immunodeficiency diseases, and its prevalence differs significantly from country to country and is more complex than this average in several countries. Therefore, the occurrence of this category of disease is a huge growth factor for the IVIG market internationally.
- Implementation of immunoglobulin therapy: Progressions in plasma fractionation procedures and manufacturing processes have amended the safety and efficacy of IVIG treatments, thus amplifying the intravenous immunoglobulin market globally. Moreover, the development of recombinant technologies and decontamination methods has shaped highly advanced and rigorous immunoglobulin products, compacted the risk of contradictory reactions, and permitted for more targeted therapies. Therefore, these innovations ensure opportunities for evolving fresh immunoglobulin-based treatments and improved patient outcomes.
Challenges
- Increased danger of transmission: There is a potential risk of transmission when it comes to handling intravenous immunoglobulin. This caters to the evolution of virus-related infectious agents as a blood product that disrupts the upliftment of the intravenous immunoglobulin (IVIG) market. This transmission takes place only in the case of a few infectious disorders, predominantly those instigated by pathogens that knowingly impact the immune system. However, intravenous immunoglobulin ensures submissive immunity in the form of antibodies to address this situation and diminish the infection severity.
- Constraints in the supply chain system: There can be limited intravenous immunoglobulin owing to restrictions in the supply chain, which hinders the growth of the intravenous immunoglobulin market globally. In situations, where there is excessive demand as well as issues in the production procedure, the supply gets severely impacted. In addition, these restrictions can result in interruptions in treatment and possibly deteriorate patient consequences. Therefore, all these factors of poor supply chain systems can deliberately affect market expansion.
Intravenous Immunoglobulin Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.5% |
|
Base Year Market Size (2024) |
USD 16.5 billion |
|
Forecast Year Market Size (2037) |
USD 43.9 billion |
|
Regional Scope |
|
Intravenous Immunoglobulin Segmentation
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies)
Hospital pharmacy segment is projected to dominate over 62.5% intravenous immunoglobulin market share by 2037. The segment evaluates patients getting intravenous immunoglobulin therapy and identifies any negative responses or feedback to appropriate supervisory bodies. Additionally, they collaborate with healthcare providers to track patient advances and regulate treatment plans accordingly. As per the June 2022 NLM article, the use of intravenous immunoglobulin in hospitals catered to 47.9% of neurological cases, 27.5% of immunological, and 20.0% of hematological situations, thus driving the market growth.
Product (IGG, IGA, IGM, IGE, IGD)
Based on the product, the IGG segment is expected to garner a considerable share in the intravenous immunoglobulin market by the end of 2037 attributable to its prevalent use and acceptance in therapeutic practice. As stated in the July 2023 NLM article, IGG is the most copious immunoglobulin comprising a plasma absorption range of 700 to 1600 mg/dL, and this constitutes about 75% to 80% of the immunoglobulins. It is categorized into various sub-classes including IgG1, IgG2, IgG3, and IgG4, and IgA into IgA1 and IgA2. Besides, ample clinical trials have established the usefulness and protection of IGG in treating autoimmune disorders, neurological conditions, and other immune-related diseases.
Our in-depth analysis of the global IVIG market includes the following segments:
|
Distribution Channel |
|
|
Product |
|
|
Route of Administration |
|
|
Application |
|
|
End Users |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportIntravenous Immunoglobulin Industry - Regional Synopsis
North America Market Analysis
North America intravenous immunoglobulin market is estimated to capture revenue share of over 51.3% by 2037, driven by the increase in the number of cancer cases. According to the 2025 America Cancer Society Organization, 42% of cancer has been diagnosed, accounting for 840,000 latest cases in 2024. This includes 19% of cases caused due to smoking and 18% caused due to the combination of physical inactivity, poor nutrition, alcohol consumption, and excessive body weight. However, to combat the occurrence, the region is well equipped with healthcare facilities as well as governmental strategies, which in turn is highly driving market development.
The IVIG market in the U.S. is mounting exponentially owing to initiatives undertaken by organizations to promote immunoglobulin through approvals of administrative bodies. For instance, in May 2021, GC Biopharma notified that the U.S. FDA acknowledged the organization's Biologics License Application (BLA) for GC5107 (Immune Globulin Intravenous). Therefore, this be effectively implemented for the treatment of Primary Humoral Immunodeficiency (PI), a category of hereditary genetic disorders that causes an individual to have a scarce or absent immune system. Thus, the amalgamation of key players and regulatory bodies is playing a pivotal role in market growth in the country.
The intravenous immunoglobulin market in Canada is attributed based on the product utilization of immunoglobulin, rising apprehensions about suitable application, cost, and risk of deficiencies. Besides, the country focuses on the involvement of governmental considerations to ensure the provision of antibodies in dealing with blood products. As per the February 2025 Government of Canada report, there is the provision of inactivated, live oral, live intranasal, Bacille Calmette-Guerin (BCG), and yellow fever vaccines in the country for measles-mumps-rubella (MMR), measles-mumps-rubella-varicella (MMRV). All these vaccines are a huge contributor towards the upliftment of the market in the country.
Immunoglobulin Administration Guidelines
|
Immunoglobulin or blood product |
Dosage |
MMR and MMRV Administration |
|
Plasma and platelet products |
10 mL/kg, IV |
7 |
|
Whole blood |
10 mL/kg, IV |
6 |
|
Packed red blood cells |
10 mL/kg, IV |
5 |
|
Reconstituted red blood cells |
10 mL/kg, IV |
3 |
|
Washed red blood cell |
10 mL/kg, IV |
0 |
|
Cytomegalovirus immunoglobulin (CMVIg) |
150 mg/kg, IV |
6 |
|
Hepatitis B immunoglobulin (HBIg) |
0.06 mL/kg, IM |
3 |
Source: Government Of Canada February 2025
APAC Market Statistics
The intravenous immunoglobulin market in the Asia Pacific is gaining a positive influence and is anticipated to witness profitable growth during the forecast timeline. The region is subjected to increasing overpopulation due to which there is a huge demand for intravenous immunoglobulin treatment solutions. As per the 2025 UNEP report, Asia Pacific accounts for 60% of the global population and 70% of the world’s populous cities. However, the region’s resource-intensive development has come at a high price and poses a noteworthy danger to people’s welfare and the environment. Additionally, the presence of market players to drive innovation and cost-effective treatment solutions is also uplifting the market in the region.
The IVIG market in India is gaining immense traction owing to contributions made by international organizations. For instance, in May 2023, PlasmaGen Biosciences lately illustrated the certified inaugural of the company's new manufacturing plant for blood plasma-derived protein therapeutics in Kolar, Bengaluru. This innovative facility will autonomously operable blocks that support numerous operations of the manufacturing process. In addition, the facility will serve to knowingly expand the supply-demand scenario for blood-plasma-derived products at reasonable prices. Therefore, with this establishment, PlasmaGen will provide intravenous immunoglobulin drugs, resulting in regional market expansion.
The intravenous immunoglobulin (IVIG) market in China is projected to expand owing to its use as an adjunctive therapy for SFTS, denoting the heterogeneous nature of the SFTS population which eventually leads to varied and often ineffective treatments. Besides, in November 2021, Zai Lab Limited declared that the first patient has been dosed in the Greater China portion of the global registrational ADHERE study of efgartigimod among patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Therefore, the use of intravenous immunoglobulin has been proved to be effective to aid chronic illnesses in the country, thus a driving aspect for the market.
Companies Dominating the Intravenous Immunoglobulin Landscape
- Annexon, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Advanced Infusion Care (AIS Healthcare)
- Biotest AG
- GC Biopharma
- Octapharma AG
- LFB Biotechnologies
- Grifols SA
- CSL Behring
- China Biologics Products Inc.
- GC Biopharma
- Kedrion Biopharma
- BDI Pharma Inc.
- ViiV Healthcare
Leading companies in the intravenous immunoglobulin market are extensively focusing on product revolution and supervisory endorsements as ultimate approaches to uphold modest superiority. Reputable organizations have emphasized developing progressive inventions and mounting therapeutic applications while fortifying regulatory consents to augment market influence. In December 2024, Annexon, Inc. notified constructive topline outcomes from a real-world evidence (RWE) study supporting ANX005 as a probable treatment for Guillain-Barré Syndrome (GBS) in comparison to intravenous immunoglobulin (IVIg) and plasma exchange (PE).
ANX005 is the most progressive targeted immunotherapy suitable for the development of GBS. It has been effectively designed to swiftly block C1q and complement activity with a solo amount to stop disease movement during the critical progressive phase of the condition. Therefore, patients treated with this immunotherapy displayed rapid and superior enhancement in muscle strength and infirmity when compared to patients in the matched IGOS cohort treated with IVIg or PE. Moreover, ANX005-treated patients were detected to devote less time to ventilation as well as less time in the intensive care unit (ICU). Thereby, this advanced immunotherapy constitutes a positive impact on the market globally.
Here's the list of some key players:
In the News
- In January 2025, Advanced Infusion Care (AIC), a part of AIS Healthcare, offered ALYGLO, which has been manufactured by GC Biopharma, for the treatment of patients with primary humoral immunodeficiency (PI) in adults. This is an intravenous immunoglobulin that comprises 10% of liquid content to aid immunodeficiency.
- In December 2024, GC Biopharma announced its acquisition of the overall stakes of ABO Holdings at USD 96 billion, intending to suggestively improve its blood products business in the United States. Also, this planned acquisition is aimed at fortifying a steady supply of raw materials for the development of its blood product business.
Author Credits: Radhika Pawar
- Report ID: 1334
- Published Date: Mar 28, 2025
- Report Format: PDF, PPT
